Male Urethral Stricture
Urethral stricture disease is one of the oldest documented conditions in urology — present in Egyptian papyri, treated by Sushruta, and still affecting millions of men worldwide. It is defined as any pathological narrowing of the anterior urethra caused by scar tissue formation within the urethral epithelium and surrounding corpus spongiosum.[1] Despite its antiquity, management has undergone fundamental transformation over the past three decades, driven by a shift from repeated endoscopic palliation toward durable reconstructive repair.
Epidemiology
The estimated prevalence of urethral stricture in developed countries is approximately 0.9%, though this likely underestimates the true burden of disease given underdiagnosis.[2] Population-level data suggest a prevalence of 1–9 per 1,000 men, with incidence rising steeply with age — men over 85 face a 12-fold higher risk than younger cohorts.[1]
Peak incidence occurs at approximately age 45, though strictures are uncommon in those younger than 20 or older than 70. The median age at presentation is approximately 64 years.[4]
Anatomic Distribution
Approximately 80–92% of strictures involve the anterior urethra.[5][3]
| Location | Proportion of All Strictures |
|---|---|
| Bulbar urethra | 40–47% (most common) |
| Penile urethra | ~30% |
| Multifocal / panurethral | 10–15% |
| Posterior urethra | 8–20% |
The bulbar urethra's predominance reflects its susceptibility to perineal trauma, instrumentation, and the unique vascularity of the bulbospongiosus region. Posterior strictures — membranous and prostatic — are almost exclusively iatrogenic or traumatic.[4]
Etiology
The etiology of urethral stricture disease has shifted dramatically in the modern era. In developed countries, iatrogenic causes now predominate; in low-income countries, trauma remains the leading cause due to road traffic injuries and limited healthcare infrastructure.[1]
Etiology Overview
| Category | Proportion | Key Causes |
|---|---|---|
| Iatrogenic | 38–52% | Urethral catheterization (16–60% of iatrogenic), TURP (9–40%), hypospadias repair (12–16%), prostatectomy (21–25% in men >45 yr) |
| Idiopathic | 20–36% | Unknown; once attributed to subclinical repeated perineal trauma (SRPT), now challenged |
| Inflammatory | 14–16% | STIs (gonorrhea historically dominant), predominantly penile urethra (48%) |
| Lichen sclerosus (LS) | 13–14% | Mean stricture length 7.45 cm; penile predominance; possible urethral cancer association |
| Traumatic | 11–22% | Pelvic fracture = 63% of trauma strictures; posterior urethra predominates |
:::note Idiopathic Strictures: Rethinking "Microtrauma" Historically, idiopathic strictures were attributed to subclinical and repeated perineal trauma (SRPT). However, deep phenotyping studies have demonstrated that patients with idiopathic strictures have SRPT exposure rates similar to those with known etiologies — challenging this conventional wisdom. Shared inflammatory biomarker profiles between idiopathic and lichen sclerosus strictures suggest a systemic inflammatory predisposition may underlie many "idiopathic" cases.[7] :::
Etiology by Age and Location
Etiology varies significantly by patient age and stricture location:[6][5]
| Population | Predominant Etiologies |
|---|---|
| Age <45 years | Idiopathic, hypospadias surgery, pelvic fracture trauma |
| Age ≥45 years | Iatrogenic (68% in those over 60): TURP, prostatectomy |
| Penile strictures | Hypospadias repair, idiopathic, urethral catheterization, lichen sclerosus |
| Bulbar strictures | Idiopathic, TURP |
| Membranous/prostatic | Iatrogenic (post-prostatectomy), pelvic fracture |
| Multifocal/panurethral | Urethral catheterization |
Pathophysiology
Tissue-Level Mechanism
Urethral stricture formation results from fibrosis and scar tissue development in response to injury — whether traumatic, inflammatory, or ischemic.[8] The pathophysiologic cascade:
- Epithelial injury → bleeding, extravasation of urine into the corpus spongiosum
- Inflammatory cell infiltration → myofibroblasts and multinucleated giant cells
- Dysregulated collagen remodeling → synthesis exceeds degradation; Type III collagen predominates over Type I, reducing urethral elasticity and compliance
- Progressive spongiofibrosis → the scar encases and compresses the urethral lumen
The depth and extent of spongiofibrosis is the primary determinant of stricture severity and is the target of the Devine classification system.
Histopathology
Recent detailed histopathologic studies have clarified stricture biology:[9]
- Chronic inflammation is present in 44% of stricture specimens, with lymphocytes as the predominant cell type (86% of inflammatory cases) and plasma cells in 12%
- Inflammation severity: minimal 20%, mild 39%, moderate 39%, severe 2%
- Inflammation patterns differ by etiology: mild-to-severe inflammation in 27% of trauma strictures, 54% of idiopathic, and 48% of LS strictures (P = 0.036)
- Isolated bulbomembranous strictures show largely absent inflammation (only 9%), suggesting direct mechanical injury rather than an inflammatory mechanism
- Fibrosis does not significantly differ between etiologies, supporting a common final pathway of scar formation regardless of initiating insult[7]
Molecular Biomarkers
Deep phenotyping has identified systemic inflammatory and fibrotic biomarkers elevated in stricture patients versus controls:[7]
- Interleukin-9 (IL-9) — elevated in inflamed strictures; correlates with inflammation severity (Spearman's ρ 0.224, P = 0.014)
- Platelet-derived growth factor-BB (PDGF-BB)
- CCL5
These cytokines are implicated in fibrotic conditions in other organ systems and may represent future therapeutic targets for scar prevention or modulation.
Clinical Presentation
Symptoms
Men most commonly present with obstructive voiding symptoms (LUTS), reported by over 90% of patients:[1][8]
- Weak or reduced urinary stream
- Incomplete bladder emptying
- Urinary hesitancy and straining to void
- Intermittent or split stream
- Post-void dribbling
- Spraying of urine
Irritative symptoms may also occur: dysuria, urinary frequency, urgency, and nocturia.
Additional presentations include:
- Acute urinary retention (AUR) — present in 32.6% of patients at diagnosis[10]
- Recurrent urinary tract infections (particularly with elevated post-void residuals)
- Rising post-void residual volumes
- Hematuria
- Urinary incontinence (overflow or post-void dribbling)
- Ejaculatory dysfunction (minority of patients)
- Rare: urethral carcinoma, Fournier's gangrene, bladder atonia[8]
Physical Examination
- Palpable urethral thickening or induration — correlates with severity of spongiofibrosis
- White plaques or patches on the glans/prepuce — characteristic of lichen sclerosus
- Palpably distended bladder — chronic urinary retention
- Perineal/scrotal fluctuance — urethral abscess or extravasation (urgent)
Complications and Natural History
Urethral stricture is frequently a morbid condition: 40.6% of patients experience at least one stricture-related complication.[10]
| Complication | Incidence |
|---|---|
| Acute urinary retention | 32.6% |
| Difficult catheterization requiring emergent intervention | 16.0% |
| Urethral abscess or urosepsis | 5.0% |
| Renal failure | 3.1% |
| Life-threatening complication (any) | 7.0% |
Risk factors for complications (multivariate analysis):[10]
- Longer stricture length (OR 1.1 per cm)
- Absence of preceding LUTS (OR 3.8) — strictures presenting acutely without warning
- Posterior stenosis (OR 3.0)
- Trauma etiology (OR 1.6)
If untreated, strictures cause progressive obstructive uropathy with potential renal impairment. The severity of disease at presentation is substantial — 83% of strictures cause obstruction of more than two-thirds of the urethral lumen.[4]
Female Urethral Stricture
Female urethral strictures are most commonly iatrogenic, often following traumatic catheterization or multiple dilations that cause fibrotic healing from bleeding and extravasation.[1] Other causes include blunt pelvic trauma, obstetric complications (cephalopelvic disproportion), malignancy, radiation, urethrovaginal atrophy, recurrent infections, and skin diseases (lichen planus, lichen sclerosus).
Diagnosis is challenging due to non-specific presentation and unclear diagnostic criteria. Patients present with LUTS, recurrent UTIs, hesitancy, poor flow, frequency, urgency, urethral pain, elevated PVR, or AUR. Inability to pass even a small catheter due to distal stenosis is strongly suggestive.
Diagnosis & Workup
Diagnosis requires endoscopic or radiographic confirmation in the setting of clinical suspicion.[1] Stricture length and location are critical for treatment planning.
Imaging
| Modality | Role | Key Points |
|---|---|---|
| Retrograde Urethrography (RUG) | Gold standard for anterior urethra | Identifies location, length, severity; performed with fluoroscopy |
| Voiding Cystourethrography (VCUG) | Posterior urethra; functional significance | Combined RUG+VCUG for complete urethral mapping |
| Sonourethrography (SUG) | Spongiofibrosis assessment | Superior to RUG for measuring true stricture length and depth of fibrosis in bulbar urethra; emerging role |
| MRI | Complex posterior injuries | Best for pelvic fracture urethral injuries (PFUI) — defines distraction defect length and anatomy |
Diagnostic Procedures
Uroflowmetry: A characteristic "flat-topped" or plateau-shaped tracing with peak flow (Qmax) <10–12 mL/s is highly suggestive of stricture disease.
Urethrocystoscopy: Provides direct visualization of the urethral lumen. Key endoscopic findings:
- Epithelial pallor
- Reduced tissue elasticity
- Inability to advance the scope (tight strictures)
- Scarring pattern and distribution
Urodynamics: Generally not routinely indicated unless coexisting bladder dysfunction (e.g., neurogenic bladder, OAB, DUA) is suspected.
Classification & Grading
EAU Lumen-Based Grading System
| Category | Description | Lumen Caliber |
|---|---|---|
| 1 | Subclinical | >16 Fr |
| 2 | Low grade | 11–15 Fr |
| 3 | High grade | 4–10 Fr |
| 4 | Nearly obliterative | 1–3 Fr |
| 5 | Obliterative | 0 Fr |
Devine Classification (Spongiofibrosis Depth)
Grades strictures by depth of fibrosis from mucosal-only involvement to full-thickness fibrosis extending outside the corpus spongiosum. Deeper fibrosis predicts higher recurrence after endoscopic management and favors open reconstruction.
LSE System
Some guidelines advocate standardized reporting of Length, Severity, and Etiology (LSE) to better predict surgical outcomes and allow cross-study comparison.
Management
Intervention is indicated for any of the following:
- Symptomatic LUTS attributable to stricture
- Acute urinary retention
- Recurrent urinary tract infections
- Bladder calculi
- Rising post-void residual threatening upper tract function
- Subclinical strictures in patients undergoing transurethral procedures (to facilitate access)
- DVIU should not be used for penile urethral strictures or strictures >2 cm in length — recurrence approaches 100%
- Genital skin grafts and flaps are strictly contraindicated in patients with lichen sclerosus — LS will recur in genital skin used for reconstruction
- Hair-bearing skin must never be used for urethral substitution — causes calculi, infection, and obstruction
- Tubularized grafts without an adequate vascular bed have high restenosis rates and should be avoided
Observation
Asymptomatic, subclinical strictures (EAU Category 1, >16 Fr) may be managed with active surveillance. Intervention is deferred until symptoms develop or lumen narrows to a clinically relevant degree.
Endoscopic Management: Dilation and DVIU
Direct Visual Internal Urethrotomy (DVIU) and urethral dilation are the most commonly performed procedures for stricture disease. They are appropriate as a first-line treatment for short (<2 cm) bulbar strictures and offer equivalent long-term outcomes to each other — they are interchangeable.[1]
Key limitations:
- Success rates decline precipitously with repeat procedures — DVIU success rates approach 0% after multiple attempts[1]
- Endoscopic treatment of strictures >2 cm achieves only ~20% success[1]
- Penile strictures are unlikely to respond to dilation or urethrotomy
- Repeated DVIU promotes progressive spongiofibrosis, making subsequent urethroplasty more complex
Urethroplasty may be offered as primary treatment even for short bulbar strictures when the patient prefers definitive repair, understands the trade-off of higher short-term morbidity for superior durability.[1]
Drug-Coated Balloons
Drug-coated balloons (DCBs) have emerged as an option for recurrent bulbar strictures. The AUA restricts their use to this indication, noting insufficient efficacy data for penile strictures or repeated use.[1]
Urethroplasty
Urethroplasty is the definitive treatment for urethral stricture disease. It is recommended upfront for long bulbar strictures, penile strictures, and recurrent strictures after failed endoscopic management.
By Stricture Location and Length
| Stricture Type | Preferred Approach | Success Rate |
|---|---|---|
| Short bulbar (<2 cm) | EPA or DVIU (equivalent first-line); urethroplasty for definitive repair | EPA: 90–95% |
| Long bulbar (≥2 cm) | Buccal mucosa graft (BMG) substitution urethroplasty | BMG: >80% |
| Penile | Single-stage urethroplasty (penile flap or OMG); avoid endoscopic Rx | 75–85% |
| Recurrent after endoscopy | Urethroplasty (OPEN trial: HR 0.52 vs. urethrotomy) | Superior durability |
| Panurethral / complex | Multi-stage or combined techniques at specialized center | Variable |
Excision and Primary Anastomosis (EPA)
Indicated for short (<2–3 cm), non-inflammatory bulbar strictures, particularly traumatic or post-TURP. The scarred segment is excised and the healthy urethral ends anastomosed primarily. Success rates of 90–95% are maintained at long-term follow-up.[1]
For short bulbar strictures, non-transecting (vessel-sparing) substitution urethroplasty results in fewer penile complications (penile shortening, erectile dysfunction) compared to transecting techniques.[1]
Substitution (Graft/Flap) Urethroplasty
Indicated for longer strictures, multiple prior repairs, compromised local tissue, and penile involvement.
Oral mucosa is the first-choice graft material:[1]
- Buccal mucosal graft (BMG) and lingual mucosal graft (LMG) are equivalent alternatives — meta-analysis shows no difference in success rates (RR 1.03, 95% CI 0.96–1.10)[1]
- Lingual mucosa is thinner and may offer advantages for distal urethral and meatal reconstruction[1][14]
- Buccal mucosa properties: thick epithelium resistant to wet environment, thin vascularized lamina propria, accessible harvest, minimal donor morbidity
Technique selection by stricture characteristics:[14]
| Technique | Indication |
|---|---|
| Ventral or dorsal onlay BMG | Bulbar strictures (comparable success either approach) |
| Barbagli dorsal onlay | Bulbar; graft quilted to tunica albuginea — gold standard |
| Two-sided dorsal + ventral onlay (Palminteri) | Obliterative bulbar segments |
| Augmented anastomotic urethroplasty | Combining excision with onlay for moderate-length bulbar strictures |
| Asopa technique (dorsal inlay via ventral sagittal urethrotomy) | Penile strictures |
| Kulkarni technique (dorsolateral onlay, one-sided dissection) | Penile and panurethral strictures |
| Penile fasciocutaneous flap (Orandi) | Penile strictures — especially without LS |
For complex multi-segment strictures (>10 cm spanning penile and bulbar urethra), reconstruction uses one-stage or multi-stage techniques with OMG, penile fasciocutaneous flaps, or combinations. These cases should be performed at high-volume reconstructive centers.[1]
:::note The OPEN Trial The landmark OPEN trial (Goulao et al., Eur Urol 2020) randomized men with recurrent bulbar urethral stricture to open urethroplasty versus endoscopic urethrotomy. While both treatments improved voiding symptoms similarly at 24 months, urethroplasty resulted in significantly fewer reinterventions (hazard ratio 0.52, 95% CI 0.31–0.89).[11][12] This RCT provides the strongest evidence for urethroplasty superiority in the recurrent setting. :::
Alternative Management
Perineal urethrostomy — a permanent perineal stoma — may be offered as a definitive alternative to urethroplasty for patients with complex strictures, multiple failed repairs, significant medical comorbidities precluding long surgery, or patient preference. Voiding via perineal stoma is unobstructed, though surgical revision may be needed over time.[1]
Suprapubic cystostomy for "urethral rest" may be placed prior to definitive urethroplasty in patients who are catheter-dependent or on intermittent self-dilation, allowing urethral inflammation to resolve before reconstruction.[1]
Outcomes & Efficacy
| Treatment | Success Rate | Notes |
|---|---|---|
| DVIU / Dilation (primary, short bulbar) | ~50–80% at 1 yr | Declines steeply with recurrence and repeat procedures |
| DVIU (repeat / strictures >2 cm) | ~0–20% | Should not be offered repeatedly |
| EPA urethroplasty | 90–95% | Best long-term outcomes for short bulbar/traumatic strictures |
| BMG substitution urethroplasty | >80% | For longer and complex strictures |
| Penile flap urethroplasty | 75–85% | Comparable to OMG for penile strictures |
Complications
Minor (common): UTI, perineal pain, hematuria, dysuria, temporary urinary retention.
Major (uncommon but serious):
- Erectile dysfunction — risk increased with transecting versus non-transecting EPA; preserved in nerve-sparing approaches
- Fournier's gangrene — rare; from urinary extravasation in neglected or infected strictures
- Renal failure — from chronic obstructive uropathy
- Malignant degeneration — rare squamous cell carcinoma arising in long-standing inflammatory strictures (particularly LS-associated)
- Urethrocutaneous fistula — after urethroplasty, typically closes spontaneously
Follow-Up
Uroflowmetry is the most common follow-up tool used by reconstructive urologists — a non-invasive means of detecting recurrent obstruction before symptoms develop.[15] Standard practice includes:
- Uroflowmetry at 3 months, 6 months, then annually
- Post-void residual measurement
- Flexible cystoscopy if uroflow deteriorates
- Patient-reported outcome measures (symptom scores)
Practice Patterns and Guideline Adherence
Despite clear guideline recommendations, significant practice variation persists globally. A 2026 survey of Turkish urologists found that only 7% chose urethroplasty for primary 1–2 cm bulbar strictures, while 72% preferred DVIU with dilation, and 76.5% performed DVIU ≥4 times for recurrent cases — in direct conflict with guideline recommendations against repeated endoscopic management.[16]
In contrast, following publication of the 2016 AUA Guidelines, population-based data show a 0.62% annual increase in urethroplasty after failed endoscopic treatment, suggesting gradual adoption of evidence-based practice.[13]
European reconstructive urology experts demonstrate high procedural volume: 91.8% perform urethroplasty with grafts as their most frequent treatment, with 55.3% performing >20 urethroplasties annually.[15] Academic urologists demonstrate better guideline adherence than non-academic peers.[16]
References
1. Wessells H, Morey A, Souter L, Rahimi L, Vanni A. "Urethral Stricture Disease Guideline Amendment." J Urol. 2023;210(1):64–71. doi:10.1097/JU.0000000000003482
2. Tritschler S, Roosen A, Füllhase C, Stief CG, Rübben H. "Urethral Stricture: Etiology, Investigation and Treatments." Dtsch Arztebl Int. 2013;110(13):220–226. doi:10.3238/arztebl.2013.0220
3. Palminteri E, Berdondini E, Verze P, et al. "Contemporary Urethral Stricture Characteristics in the Developed World." Urology. 2013;81(1):191–196. doi:10.1016/j.urology.2012.08.062
4. de Farias RB, Neto FTL, de Aguiar Cavalcanti G, Martins FE, Lima SVC. "Evaluation of the Etiological Profile, Age and Findings in Retrograde and Voiding Urethrocystography of Men With Urethral Stricture." Sci Rep. 2025;15(1):5935. doi:10.1038/s41598-025-89389-z
5. Astolfi RH, Lebani BR, Krebs RK, et al. "Specific Characteristics of Urethral Strictures in a Developing Country (Brazil)." World J Urol. 2019;37(4):661–666. doi:10.1007/s00345-019-02696-9
6. Lumen N, Hoebeke P, Willemsen P, et al. "Etiology of Urethral Stricture Disease in the 21st Century." J Urol. 2009;182(3):983–987. doi:10.1016/j.juro.2009.05.023
7. Gutierrez WR, Luo Y, Dahmoush L, et al. "Deep Phenotyping the Anterior Urethral Stricture: Characterizing the Relationship Between Inflammation, Fibrosis, Patient History, and Disease Pathophysiology." J Urol. 2024;212(1):153–164. doi:10.1097/JU.0000000000003962
8. Wong SS, Aboumarzouk OM, Narahari R, O'Riordan A, Pickard R. "Simple Urethral Dilatation, Endoscopic Urethrotomy, and Urethroplasty for Urethral Stricture Disease in Adult Men." Cochrane Database Syst Rev. 2012;12:CD006934. doi:10.1002/14651858.CD006934.pub3
9. Grimes MD, Tesdahl BA, Schubbe M, et al. "Histopathology of Anterior Urethral Strictures: Toward a Better Understanding of Stricture Pathophysiology." J Urol. 2019;202(4):748–756. doi:10.1097/JU.0000000000000340
10. King C, Rourke KF. "Urethral Stricture Is Frequently a Morbid Condition: Incidence and Factors Associated With Complications Related to Urethral Stricture." Urology. 2019;132:189–194. doi:10.1016/j.urology.2019.07.013
11. Goulao B, Carnell S, Shen J, et al. "Surgical Treatment for Recurrent Bulbar Urethral Stricture: A Randomised Open-Label Superiority Trial of Open Urethroplasty Versus Endoscopic Urethrotomy (The OPEN Trial)." Eur Urol. 2020;78(4):572–580. doi:10.1016/j.eururo.2020.06.003
12. Pickard R, Goulao B, Carnell S, et al. "Open Urethroplasty Versus Endoscopic Urethrotomy for Recurrent Urethral Stricture in Men: The OPEN RCT." Health Technol Assess. 2020;24(61):1–110. doi:10.3310/hta24610
13. Cabral JD, Alkassis M, Khalafalla K, et al. "Contemporary Trends in the Management of Urethral Stricture Disease in the Era of the AUA Guidelines." Urology. 2025. doi:10.1016/j.urology.2025.07.054
14. Horiguchi A. "Substitution Urethroplasty Using Oral Mucosa Graft for Male Anterior Urethral Stricture Disease: Current Topics and Reviews." Int J Urol. 2017;24(7):493–503. doi:10.1111/iju.13356
15. Campos-Juanatey F, Fes-Ascanio E, Adamowicz J, et al. "Contemporary Management of Male Anterior Urethral Strictures by Reconstructive Urology Experts — Results From an International Survey Among ESGURS Members." J Clin Med. 2022;11(9):2353. doi:10.3390/jcm11092353
16. Kaçtan Ç, Abali T, Vosoughi O, et al. "Management of Urethral Stricture: Translating Guidelines Into Clinical Practice." World J Urol. 2026;44(1):212. doi:10.1007/s00345-026-06312-5